Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Human ADRBK1 cell lysate

Cat.No. : ADRBK1-625HCL
Product Overview : Human ADRBK1 / BARK1 derived in Baculovirus-Insect cells. The whole cell lysate is provided in 1X Sample Buffer.Browse all transfected cell lysate positive controls
  • Specification
  • Gene Information
  • Related Products
Source : Baculovirus-Insect Cells
Species : Human
Preparation method : Transfected cells were cultured for 48hrs before collection. The cells were lysed in modified RIPA buffer with cocktail of protease inhibitors. Cell debris was removed by centrifugation and then centrifuged to clarify the lysate. The cell lysate was boiled for 5 minutes in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.
Lysis buffer : Modified RIPA Lysis Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
Quality control Testing : 12.5% SDS-PAGE Stained with Coomassie Blue
Recommended Usage : 1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.2. Re-dissolve the pellet using 200μL pure water and boiled for 2-5 min.3. Store it at -80°C. Recommend to aliquot the cell lysate into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.Notes:The lysate is ready to load on SDS-PAGE for Western blot application. If dissociating conditions are required, add reducing agent prior to heating.
Stability : Samples are stable for up to twelve months from date of receipt at -80°C
Storage Buffer : 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
Storage Instruction : Lysate samples are stable for 12 months from date of receipt when stored at -80°C. Avoid repeated freeze-thaw cycles. Prior to SDS-PAGE fractionation, boil the lysate for 5 minutes.
Gene Name : ADRBK1 adrenergic, beta, receptor kinase 1 [ Homo sapiens ]
Official Symbol : ADRBK1
Synonyms : ADRBK1; adrenergic, beta, receptor kinase 1; beta-adrenergic receptor kinase 1; BARK1; GRK2; beta-ARK-1; G-protein coupled receptor kinase 2; BETA-ARK1; FLJ16718;
Gene ID : 156
mRNA Refseq : NM_001619
Protein Refseq : NP_001610
MIM : 109635
UniProt ID : P25098
Chromosome Location : 11q13
Pathway : CXCR4-mediated signaling events, organism-specific biosystem; Ca-dependent events, organism-specific biosystem; CaM pathway, organism-specific biosystem; Calmodulin induced events, organism-specific biosystem; Chemokine signaling pathway, organism-specific biosystem; Chemokine signaling pathway, conserved biosystem; DAG and IP3 signaling, organism-specific biosystem;
Function : ATP binding; Edg-2 lysophosphatidic acid receptor binding; G-protein coupled receptor kinase activity; alpha-2A adrenergic receptor binding; beta-adrenergic receptor kinase activity; nucleotide binding; protein binding; protein kinase activity;

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (8)

Ask a question
Can ADRBK1 inhibitors be used to treat respiratory diseases? 12/19/2022

ADRBK1 inhibitors have shown potential as a treatment for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) in preclinical studies. ADRBK1 is involved in the regulation of airway tone and smooth muscle contraction, and ADRBK1 inhibition has been shown to improve airway function and reduce inflammation in preclinical models of asthma and COPD. However, more research is needed to determine the efficacy and safety of ADRBK1 inhibitors in human clinical trials for these indications.

Are there any genetic mutations that affect ADRBK1 proteins? 05/17/2021

Yes, several genetic mutations have been identified that affect ADRBK1 proteins, leading to functional alterations and disease susceptibility. For example, a common variant in the ADRBK1 gene, known as the ADRBK1 A>G polymorphism, has been associated with increased risk of heart failure, hypertension, and other cardiovascular diseases. Other studies have linked mutations in ADRBK1 with conditions like asthma, diabetes, and Alzheimer's disease, although the exact mechanisms by which these mutations contribute to pathology are not fully understood.

What are the potential risks associated with modulating ADRBK1 activity or expression? 05/27/2020

Like any drug or therapeutic intervention, modulating ADRBK1 activity or expression carries potential risks and side effects. For example, blocking ADRBK1 activity could potentially lead to excessive receptor activation and signaling, causing unintended consequences and potential toxicity. Conversely, enhancing ADRBK1 activity could lead to receptor desensitization and decreased responsiveness to ligands, which could impair normal physiological processes. Therefore, the safety and efficacy of ADRBK1-targeted therapies must be carefully evaluated in preclinical and clinical studies before being implemented in the clinic.

How does ADRBK1 affect the cardiovascular system? 01/03/2020

ADRBK1, also known as beta-adrenergic receptor kinase 1, plays a crucial role in regulating signaling pathways in the cardiovascular system. It is involved in the regulation of cardiac function, blood pressure, and vascular tone. ADRBK1 is responsible for phosphorylating and desensitizing beta-adrenergic receptors, which are involved in the regulation of heart rate, contractility, and vascular tone. ADRBK1 inhibition has been shown to improve cardiac function, reduce blood pressure, and mitigate the effects of heart failure in preclinical studies. However, more research is needed to fully understand the effects of ADRBK1 inhibition on the cardiovascular system and to determine the safety and efficacy of these therapies in human clinical trials.

What research is currently being done on ADRBK1 proteins? 11/20/2019

ADRBK1 proteins continue to be an active area of research, with ongoing investigations exploring their roles in various disease processes and their potential as therapeutic targets. Some current research areas include developing more selective and potent ADRBK1 inhibitors, exploring the effects of ADRBK1 polymorphisms on disease susceptibility and drug response, and investigating the complex signaling pathways that involve ADRBK1 in different tissues and cell types. Additionally, preclinical and clinical studies are continuing to evaluate the safety and efficacy of ADRBK1-targeted therapies in various disease settings.

Are there any ADRBK1 inhibitors currently approved for clinical use? 10/13/2018

There are currently no ADRBK1 inhibitors approved for clinical use. However, several compounds are being developed as potential ADRBK1 inhibitors for use in the treatment of cardiovascular and metabolic diseases, as well as anxiety disorders and cancer. These compounds are in various stages of preclinical and clinical development, and more research is needed to determine their safety and efficacy in human clinical trials.

How are ADRBK1 proteins involved in disease processes? 07/03/2018

Dysregulation of ADRBK1 activity has been implicated in several disease processes, including cardiovascular disease, immune dysfunction, and cancer. In cardiovascular disease, elevated levels of ADRBK1 have been associated with impaired cardiac function, while decreased levels have been linked to hypertension and myocardial infarction. In immune dysfunction, ADRBK1 contributes to the development of inflammatory responses, and increased activity has been observed in conditions like asthma, rheumatoid arthritis, and sepsis. In cancer, ADRBK1 has been shown to promote tumor growth and metastasis.

Are there any drugs that target ADRBK1 proteins? 04/21/2017

Yes, there are several drugs that target ADRBK1 proteins. These include small molecule inhibitors that block ADRBK1 activity and prevent receptor desensitization, as well as compounds that modulate ADRBK1 expression or activity indirectly. Some of these drugs have shown promise in preclinical and clinical studies for treating conditions like heart failure, hypertension, and asthma.

Customer Reviews (4)

Write a review
Reviews
04/13/2021

    The bands of proteins in the Western Blotting experiment were very clear

    05/26/2019

      The ADRBK1 protein is of exceptional quality and is precisely what I need for my experimental purposes.

      11/15/2017

        With confidence in the protein's quality and the assistance provided by the supplier, I believe this is the ideal protein to meet my experimental needs.

        02/18/2016

          I am confident that it will provide reliable and consistent results.

          Ask a Question for All ADRBK1 Products

          Required fields are marked with *

          My Review for All ADRBK1 Products

          Required fields are marked with *

          0

          Inquiry Basket

          cartIcon
          logo

          FOLLOW US

          Terms and Conditions        Privacy Policy

          Copyright © 2024 Creative BioMart. All Rights Reserved.

          Contact Us

          • /

          Stay Updated on the Latest Bioscience Trends